http://www.futureprescriber.co.uk Future Prescriber current issue RSS Feed http://www.futureprescriber.co.uk/details/journalArticle/759159/The_promise_of_future_treatments_in_AF_is_it_all_over_for_warfarin.html Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd. 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/759167/The_promise_of_future_treatments_in_AF_is_it_all_over_for_warfarin.html Aspirin and warfarin are currently the only treatment options for patients presenting with atrial fibrillation at risk of stroke. New oral direct thrombin inhibitors may offer an additional choice or viable alternative. Here we consider their potential role with a focus on dabigatran. Copyright © 2010 John Wiley & Sons, Ltd. 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/759161/Management_of_chronic_pain_current_and_future_options.html Chronic pain is surprisingly prevalent and, if left untreated, can lead to significant limitations for the sufferer including restricted mobility and possible job loss. Pain has also been shown to be the reason for 40% of patient visits to GPs each year. This results in a substantial economic burden not only for those involved but also for the wider economy. Here we review the current options for pain management and look at new treatments in the pipeline. Copyright © 2010 John Wiley & Sons,... 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/759169/Management_of_chronic_pain_current_and_future_options.html Chronic pain is surprisingly prevalent and, if left untreated, can lead to significant limitations for the sufferer including restricted mobility and possible job loss. Pain has also been shown to be the reason for 40% of patient visits to GPs each year. This results in a substantial economic burden not only for those involved but also for the wider economy. Here we review the current options for pain management and look at new treatments in the pipeline. Copyright © 2010 John Wiley & Sons,... 2010-07-13T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589011/New_directions_in_cancer_therapy__HDAC_inhibitors.html The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non-Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve Schey considers the place of HDACis in future cancer therapy. Copyright... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589013/New_directions_in_cancer_therapy__HDAC_inhibitors.html The HDACis (histone deacetylation inhibitors) are an active class of drugs that have been used to treat a wide variety of tumours including breast cancer, prostate cancer, multiple myeloma, thyroid cancer and Hodgkin's and non-Hodgkin's lymphoma. One HDAC, vorinostat, has been licensed by the FDA, but more work is needed to identify and delineate the histone and nonhistone targets of these agents. In this article, Dr Steve Schey considers the place of HDACis in future cancer therapy. Copyright... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589015/Grnenthal_developing_and_expanding_in_pain_research.html This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Grünenthal and its current portfolio, and look at the current pipeline and areas of research interest. Copyright © 2010 John Wiley & Sons, Ltd. 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589017/Grnenthal_developing_and_expanding_in_pain_research.html This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Grünenthal and its current portfolio, and look at the current pipeline and areas of research interest. Copyright © 2010 John Wiley & Sons, Ltd. 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/589021/COPD_management_new_and_existing_therapy_options.html Early detection and appropriate management of chronic obstructive pulmonary disease (COPD) may help to reduce the high mortality and morbidity associated with this disease. New pharmacological treatments for COPD, along with the implementation of recommendations of the National Strategy for COPD due for publication later this year, will help to raise the standard of care and improve outcomes for COPD patients. In this article, Professor Price and Rhonda Siddall consider current COPD therapy... 2010-03-15T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520589/AntiTNFalpha_drugs__moving_into_the_mainstream.html Anti-TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti-TNF-alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd. 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520591/AntiTNFalpha_drugs__moving_into_the_mainstream.html Anti-TNF drugs are a major treatment advance in the management of inflammatory disorders such as rheumatoid arthritis, and are typically considered following unsuccessful treatment with conventional disease-modifying antirheumatic drugs (DMARDs). Drs Chris Deighton and Tina Ding review the available anti-TNF-alpha drugs, and consider their future place in therapy. Copyright © 2009 John Wiley & Sons, Ltd. 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520593/Quetiapine_a_new_option_in_bipolar_depression.html Bipolar disorder is a condition characterised by periods of depression, mania or depressive and manic symptoms appearing together. Depression is the predominant symptom and is often responsible for poor quality of life. The condition is treatable, but poor compliance is a major problem. Pharmacological treatments include lithium (although it has poor efficacy in depression), valproate and olanzapine (which can cause metabolic syndrome). In this article, Dr Palazidou considers quetiapine, a... 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520595/Quetiapine_a_new_option_in_bipolar_depression.html Bipolar disorder is a condition characterised by periods of depression, mania or depressive and manic symptoms appearing together. Depression is the predominant symptom and is often responsible for poor quality of life. The condition is treatable, but poor compliance is a major problem. Pharmacological treatments include lithium (although it has poor efficacy in depression), valproate and olanzapine (which can cause metabolic syndrome). In this article, Dr Palazidou considers quetiapine, a... 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520599/Certolizumab_pegol_a_new_option_for_rheumatoid_arthritis.html Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd. 2009-12-24T00:00:00Z http://www.futureprescriber.co.uk/details/journalArticle/520601/Certolizumab_pegol_a_new_option_for_rheumatoid_arthritis.html Rheumatoid arthritis (RA) presents a significant burden to healthcare in the UK. New biological therapies have advanced treatment but at a high cost to the NHS. Certolizumab pegol is a new TNF inhibitor, providing an additional treatment option for RA. In this article Dr Ma and Dr Choy consider the efficacy of certolizumab pegol, and where it may fit into the RA armoury. Copyright © 2009 John Wiley & Sons, Ltd. 2009-12-24T00:00:00Z